CANVAS - CANagliflozin cardioVascular Assessment Study

NCT01032629 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4330

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2
Cardiovascular Diseases
Risk Factors

Interventions

DRUG: Placebo
DRUG: Canagliflozin (JNJ-28431754) 100 mg
DRUG: Canagliflozin (JNJ-28431754) 300 mg

Sponsor

Janssen Research & Development, LLC

Collaborators

[object Object]